Orphapacket:
  AverageAgeOfDeaths:
    AverageAgeOfDeath:
    - value: any age
  AverageAgeOfOnsets:
    AverageAgeOfOnset:
    - value: All ages
  Childs:
  - Child:
      Genes:
      - Gene:
          ExternalReferences:
          - Reference: '17098'
            Source: HGNC
          - Reference: '606241'
            Source: OMIM
          Label: dicer 1, ribonuclease III
          Symbol: DICER1
      Label: Gynandroblastoma
      ORPHAcode: '99914'
  - Child:
      Genes:
      - Gene:
          ExternalReferences:
          - Reference: '1092'
            Source: HGNC
          - Reference: '605597'
            Source: OMIM
          Label: forkhead box L2
          Symbol: FOXL2
      - Gene:
          ExternalReferences:
          - Reference: '17098'
            Source: HGNC
          - Reference: '606241'
            Source: OMIM
          Label: dicer 1, ribonuclease III
          Symbol: DICER1
      Label: Maligant granulosa cell tumor of the ovary
      ORPHAcode: '99915'
  - Child:
      Genes:
      - Gene:
          ExternalReferences:
          - Reference: '17098'
            Source: HGNC
          - Reference: '606241'
            Source: OMIM
          Label: dicer 1, ribonuclease III
          Symbol: DICER1
      Label: Malignant Sertoli-Leydig cell tumor of the ovary
      ORPHAcode: '99916'
  - Child:
      Genes: no data
      Label: Theca steroid-producing cell malignant tumor of ovary, not further specified
      ORPHAcode: '99917'
  DisorderType:
    PURL: http://www.orpha.net/ORDO/Orphanet_557495
    value: Category
  Label: Malignant sex cord stromal tumor of ovary
  ORPHAcode: '35808'
  ORPHApacketId: '35808'
  PURL: http://www.orpha.net/ORDO/Orphanet_35808
  Parents:
  - Parent:
    - Label: Malignant non-epithelial tumor of ovary
      ORPHAcode: '398940'
  Prevalences:
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Point prevalence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: United States
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: 15863154[PMID]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: Unknown
      PrevalenceGeographic: Worldwide
      PrevalenceQualification: Class only
      PrevalenceType: Point prevalence
      Source: ORPHANET
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Finland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Iceland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Ireland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Italy
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Malta
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Portugal
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Slovenia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Spain
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Switzerland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: Netherlands
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: <1 / 1 000 000
      PrevalenceGeographic: United Kingdom
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Austria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Belgium
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Bulgaria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Croatia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Czech Republic
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Estonia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Germany
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Latvia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Lithuania
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Norway
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Poland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Slovakia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  Synonyms:
  - Synonym: Malignant ovarian SCST
  - Synonym: Malignant ovarian sex cord-stromal tumor
  TextSection:
    Contents: Malignant sex cord stromal tumor (SCST) of ovary is a rare ovarian cancer
      (see this term) arising from granulosa theca sertoli and leydig cells or stromal
      fibroblasts occurring at any age and presenting with abdominal or pelvic mass
      and characterized (with the exception of fibroma) by the production of sex steroids
      resulting in manifestations of hormone excess with a relatively favorable prognosis.
    TextSectionType: Definition
  TypeOfInheritances:
    TypeOfInheritance:
    - value: Not applicable
  copyright: Orphanet (c) 2021
  creationDate: '2021-08-17 17:32:38'
  version: 1.3.7 / 4.1.7 [2020-12-03] (orientdb version)
